Scientist III

Posted 10 Hours Ago
Be an Early Applicant
Doylestown, PA
128K-160K Annually
7+ Years Experience
Biotech
The Role
The Scientist III will contribute to the preclinical development of antibody-based therapeutics by establishing core capabilities in the AI lab, leading research to generate proof-of-concept data, selecting therapeutic candidates, designing assays, and collaborating with internal teams and CROs for studies.
Summary Generated by Built In

About IGM Biosciences, Inc.


IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com.

 

Imvotamab in Autoimmune and Inflammatory Diseases

Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).


Position:

We seek a highly motivated and innovative scientist with immunology research experience and a passion to develop antibody-based therapeutics. You will play an integral role in the pre-clinical development of novel autoimmunity and inflammation therapeutics. The ideal candidate will have a proven track record of experience with core immunological assays and models (e.g., T cell proliferation, antigen recall, in vivo models of inflammatory disease) and techniques (immune cell culture, flow cytometry, ELISA, RT-PCR, etc.) The candidate will be required to coordinate and execute on research projects across multiple functional teams, both internal of IGMS and external vendors and collaborators. Strong communication skills and organizational skills are essential. A key initial responsibility will be the set up and establishment of core capabilities in the AI lab. This role involves delivering on programs through proof- of-concept in vitro and in vivo studies and advancing therapeutic candidates from early discovery to IND- enabling studies. 

Responsibilities:

  • Establish core capabilities in AI lab
  • Lead research efforts to generate proof-of-concept in vitro and in vivo data for early-stage autoimmune and inflammation programs
  • Lead therapeutic candidate selection and perform IND-enabling studies
  • Work closely with team members and CROs to develop assays and models to assess biological activity
  • Present results at internal and external meetings

Qualifications:

  • Ph.D. with 2-7 years of industry experience or with equivalent postdoctoral research experience or a Bachelor’s/ Master’s degree with 10+ years of industry experience in the field of immunology.
  • Must have hands-on experience and proficiency in one or more of the following areas: multi-color flow cytometry, complex cell-based functional assays, in vivo mouse models of disease.
  • Must be proficient with Microsoft Word, Excel, and PowerPoint, GraphPad Prism, and FlowJo.
  • Experience establishing mechanistic in vitro and ex vivo immune cell-based assays with primary immune cells from human and relevant animal species.
  • Understanding of and ability to select relevant in vivo models for mechanistic and efficacy studies.
  • Demonstrated track record of independence, critical thinking, and scientific research achievements in immunology and/or significant contributions to a discovery program or therapeutic development.
  • Highly organized with reliable time-keeping skills and able to maintain a detailed and wellorganized electronic notebook.
  • Must have strong interpersonal, collaboration, and communication skills.
  • Being a team player and respectful of others is a must.
  • Able to thrive in a fast-paced, start-up environment.
  • Able to commute to Doylestown. 

We offer a fast-paced, collaborative, team-based work environment. 

 

One of our top priorities is to maintain our employees' and their families' health and well-being. To achieve this goal, we offer comprehensive benefits with a variety of options:


Medical, dental, and vision insurance.

IGM covers the full premium amount for our employees and their dependents

FSA (Flexible Spending Account) or HSA (Health Savings Account)

STD, LTD, Basic Life and AD&D Insurance, Supplemental Life and AD&D Insurance

Voluntary Life Insurance and Disability

401(k) Plan with Employer Match

3 Weeks of Paid Time Off, 5 sick days per year, 12 holidays

Cell phone & internet subsidy

Employee Referral Bonus Program

Annual training budget for professional development

Commuter Benefit

Annual bonus program

New hire equity

Annual refresh grants

ESPP (Employee Stock Purchase Plan)

 

IGM is an equal opportunity employer that prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status, and veteran status. All qualified applicants will be considered for employment.

The Company
HQ: Mountain View, CA
229 Employees
On-site Workplace
Year Founded: 2010

What We Do

IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers.

Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies, and it is currently in a Phase 1 clinical trial. Also in our product pipeline is IGM-7354 and IGM-2644. IGM-7354 is an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to the area of PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma.

Jobs at Similar Companies

Pfizer Logo Pfizer

Senior Manager, Physical Risk Mitigation Crisis Manager

Artificial Intelligence • Healthtech • Machine Learning • Natural Language Processing • Biotech • Pharmaceutical
Hybrid
Collegeville, PA, USA
121990 Employees
117K-196K Annually

Takeda Logo Takeda

Manager, IBD Sales and Account Analytics

Healthtech • Software • Analytics • Biotech • Pharmaceutical • Manufacturing
Hybrid
Boston, MA, USA
50000 Employees

SOPHiA GENETICS Logo SOPHiA GENETICS

BioPharma Business Development Director

Artificial Intelligence • Big Data • Healthtech • Software • Biotech
3 Locations
450 Employees

Similar Companies Hiring

SOPHiA GENETICS Thumbnail
Software • Healthtech • Biotech • Big Data • Artificial Intelligence
Boston, MA
450 Employees
Pfizer Thumbnail
Pharmaceutical • Natural Language Processing • Machine Learning • Healthtech • Biotech • Artificial Intelligence
New York, NY
121990 Employees
Takeda Thumbnail
Software • Pharmaceutical • Manufacturing • Healthtech • Biotech • Analytics
Cambridge, MA
50000 Employees

Sign up now Access later

Create Free Account

Please log in or sign up to report this job.

Create Free Account